Letter by Tampaki et al Regarding Article, "Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors"

Circ Res. 2018 Aug 3;123(4):e1-e2. doi: 10.1161/CIRCRESAHA.118.313466.

Authors

Ekaterini Christina Tampaki¹, Athanasios Tampakis², Lorenz Gürke³, Costas Pantos⁴

Affiliations

¹ B Department of Propaedeutic Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
² Department of General and Visceral Surgery, Basel University Hospital, Basel, Switzerland.
³ Department of Vascular Surgery and Renal Transplant Center, Basel University Hospital, Basel, Switzerland.
⁴ Department of Pharmacology, National and Kapodistrian University of Athens, Athens, Greece.

PMID: 30355254
DOI: 10.1161/CIRCRESAHA.118.313466

No abstract available

Publication types

Letter
Comment

MeSH terms

Cardiovascular System*
Dipeptidyl-Peptidase IV Inhibitors*
Glucose
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Glucose